Gilead Sciences, a U.S. based biopharmaceutical company, will soon begin trials of the antiviral drug called Remdesivir, in an inhaled application. Earlier trials have shown promise for this possible treatment to combat the rampant worldwide virus. Hospitals have been giving Remdesivir to COVID-19 patients intravenously, which has imposed the restriction to in-hospital use only. The inhalable version could be administered via a nebulizer, which is a device often used by asthma patients to deliver therapeutic medicinal mist into the airways. Nebulizers can be portable, and readily available for use. The promising hope for this new treatment is Remdesivir is the first anti-viral drug which has been shown to be effective in treating the Coronavirus. If the inhalation trials succeed, it would make it possible to treat patients who have tested positive immediately without necessarily needing be hospitalized to do so.
Doug Garfinkel has been a writer for over 30 years, working on a wide variety of websites and publications. He currently works as a High School teacher in Great Neck, NY, while continuing to write.